NCT07226739 is a Phase 4 clinical trial of Glycerin Suppository in Encopresis, sponsored by Emory University.

Who is sponsoring NCT07226739?

NCT07226739 is sponsored by Emory University.

What drugs are being tested in NCT07226739?

Interventions in NCT07226739: Glycerin Suppository, Behavioral strategies.

What condition does NCT07226739 study?

NCT07226739 studies Encopresis, ASD.

Is NCT07226739 still recruiting?

NCT07226739 is currently not yet recruiting. Last updated 27 April 2026.

Last reviewed 2026-04-27 · How we verify

NCT07226739

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comprehensive Toileting Programming: Enuresis Treatment to a Randomized Clinical Trial of a Caregiver-Mediated Multidisciplinary Intervention for Encopresis

Not yet recruiting Phase 4 Last updated 27 April 2026

What this trial tests

Phase 4 trial testing Glycerin Suppository in Encopresis in 150 participants. Not yet recruiting.

Timeline

1 May 2026

Primary endpoint
1 January 2031

1 January 2031

Quick facts

Lead sponsor	Emory University
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	150
Start date	1 May 2026
Primary completion	1 January 2031
Estimated completion	1 January 2031
Sites	1 location across United States

Drugs / interventions tested

Glycerin Suppository — full drug profile →
Behavioral strategies

Conditions studied

Encopresis — all drugs for Encopresis →
ASD — all drugs for ASD →

Sponsor

Emory University

Who can join

Adults 5 to 12, any sex, with Encopresis or ASD. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical Global Impression Improvement (CGI-I) scale score
Time frame: 5 weeks post-baseline (Endpoint)
The CGI-I is a clinician-rated 7-point scale measuring overall change from baseline. Scores range from 1 (Very Much Improved) to 4 (Unchanged) to 7 (Very Much Worse), rated by the treatment-blind independent evaluator (IE) with all available information. CGI-I ratings of Much Improved (score of 2) or Very Much Improved (score of 1) will define positive response; all other ratings are defined as no

Sponsor's own description

The current study aims to monitor fecal continence after autistic youth complete enuresis treatment and for individuals who continue to experience encopresis after acquiring urine continence, evaluate a caregiver-mediated version of a Multidisciplinary Intervention for Encopresis (CM-MIE) delivered via telehealth to determine efficacy in a randomized clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Glycerin Suppository

Trials testing the same drug.

NCT06048614 — Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and · NA · recruiting
NCT03197922 — Treatment of Encopresis in Children With Autism Spectrum Disorders · Phase 3 · completed
NCT03355326 — Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis · Phase 4 · terminated
NCT03657407 — B&O for TLH Post-operative Pain and Nausea · Phase 4 · completed
NCT02383758 — An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders · NA · completed

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07226739 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 27 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07226739.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing